This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
Interview with Gian Luca Trinei
Read the interview with Gian Luca Trinei, Chief Compliance Officer Italy, Pfizer.
The stringency of anti-corruption and anti-bribery laws in Europe is starting to resemble or even surpass that of US legislation. What measures is the pharmaceutical industry taking to compensate for the growing number of regulations and initiatives?
The pharmaceutical industry is reacting to the growing number of initiatives through the implementation of Compliance programs which take into consideration – where possible – the multiple anticorruption and/or transparency regulations which are in place in a specific region/country.
A good example is represented by the synergy that exists while producing the FCPA trend analysis and the EFPIA transparency disclosure for several kinds of transactions undertaken with Governmental Officials or Health Care Professionals.
A similar synergy is exploited when a company has to comply with different anti-corruption laws. In our case, we have to respect both FCPA prescriptions while dealing with Governmental Officials and at the same time with local Legislative Decree 231/2001 whose (main) objective is to prevent corruption in the Public Administration.
Although the operational ways in which the two laws pursue a similar objective are quite different, it is possible to review a specific process form both points of view, exploiting controls that could satisfy the need to prevent corruption.
Pharma's reputation continues to suffer, and trust is not just something the industry communicates – it has to be earned through industry action. How do you think the industry could maintain or improve trust?
There are several actions that the Pharmaceutical industry could take to earn better trust from the society where it lives:
· Being transparent and ethical in everyday behavior;
· Being focused and inspired by the patient’s need;
· Considering the needs of all its stakeholders, particularly those of the payers in countries where the health care system has to provide assistance to patients while respecting an increasingly restricted expense budget;
· Engaging in initiatives that could improve life for all citizens and patients; respecting and exceeding the prescription of Environment, Health & Safety laws in the production plant;
All of the above behaviors might help the industry in being perceived not as a group of companies only focused on profits, but as a member of the society where they live who has a great sense of solidarity with the surrounding environment.
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?
With improved patient engagement to increased patient adherence
Chronic illnesses are commonly treated with the long-term use of medications. This treatment could be successful, however, its benefits are overshadowed by the fact that 50% of patients don't take their medications as prescribed. Reveal all the alarming numbers of non-adherence and learn how to decrease it with improved patient engagement.